Wendell Wierenga

Wendell D.
Wierenga currently works at Crinetics Pharmaceuticals, Inc., as Chairman from 2015, Cytokinetics, Inc., as Independent Director from 2011, and Dermata Therapeutics, Inc., as Independent Director from 2016.
Dr. Wierenga also formerly worked at Syrrx, Inc., as Chief Executive Officer from 1999 to 2004, Pharmacia & Upjohn, Inc., as Executive Director-Discovery Research, The Upjohn Co., as Executive Director-Discovery Research, Onyx Pharmaceuticals, Inc., as Independent Director from 2011 to 2013, Apricus Biosciences, Inc., as Independent Director from 2014 to 2019, Aspira Women's Health, Inc., as Director, Patara Pharma LLC, as Director, SRI International, as Director, XenoPort, Inc., as Independent Director from 2011 to 2016, OCERA Therapeutics LLC, as Independent Director from 2013 to 2017, Anacor Pharmaceuticals LLC, as Independent Director from 2015 to 2016, Concert Pharmaceuticals, Inc., as Independent Director from 2014 to 2019, Warner-Lambert Co., as Vice President-Medtech Ventures from 1992 to 2000, Santarus, Inc., as Executive Vice President-Research & Development from 2011 to 2014, Parke-Davis Pharmaceutical Research, Inc., as Senior Vice President-Research from 1990 to 2000, Neurocrine Biosciences, Inc., as Executive Vice President-Research & Development from 2004 to 2006, Pfizer Inc., as Senior VP-Worldwide Pharmaceutical Sciences from 1990 to 2000, and Ambit Biosciences Corp., as Executive Vice President-Research & Development from 2007 to 2011.
Dr. Wierenga received his doctorate degree from Stanford University and undergraduate degree from Hope College.